FMP
Akari Therapeutics, Plc
AKTX
NASDAQ
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
1.18 USD
0.07 (5.93%)
About
ceo
Ms. Rachelle Suzanne Jacques
sector
Healthcare
industry
Biotechnology
website
https://www.akaritx.com
exchange
NASDAQ
Description
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
CIK
0001541157
ISIN
US00972G2075
CUSIP
00972G108
Address
75/76 Wimpole Street
Phone
44 20 8004 0270
Country
GB
Employee
9
IPO Date
Jan 6, 2014
Summary
CIK
0001541157
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
00972G108
ISIN
US00972G2075
Country
GB
Price
1.18
Beta
0.96
Volume Avg.
12.16k
Market Cap
7.81M
Shares
-
52-Week
1.078-5.5
DCF
0.79
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.58
P/B
-
Website
https://www.akaritx.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest AKTX News
It looks like there's no news available.
